Olmesartan dose 5 mg
Pro Research Analysisby 
Searched over 200M research papers
Efficacy and Safety of Olmesartan 5 mg in Hypertension Management
Introduction to Olmesartan and Hypertension
Olmesartan medoxomil is an angiotensin II receptor antagonist used to manage hypertension. It is often combined with other antihypertensive agents like amlodipine to enhance efficacy. This article synthesizes research findings on the efficacy and safety of olmesartan, particularly focusing on its 5 mg dose.
Efficacy of Olmesartan/Amlodipine Combination Therapy
Several studies have demonstrated the superior efficacy of olmesartan/amlodipine combinations over monotherapy with amlodipine. In patients with moderate-to-severe hypertension not controlled by amlodipine alone, the combination of olmesartan (10-40 mg) with amlodipine (5 mg) significantly reduced 24-hour systolic and diastolic blood pressure (SBP/DBP) compared to amlodipine 5 mg alone1. This combination also showed better 24-hour blood pressure coverage and improved blood pressure lowering homogeneity1.
Dose-Dependent Efficacy in Pediatric Populations
In children and adolescents with hypertension, olmesartan medoxomil demonstrated a dose-dependent reduction in seated trough systolic and diastolic blood pressure. Low doses (2.5 or 5 mg) were effective, but higher doses (20 or 40 mg) provided more significant reductions2. This indicates that even at lower doses, olmesartan can be effective in managing hypertension in younger populations.
Safety and Tolerability
The safety profile of olmesartan, including its combination with amlodipine, has been well-documented. In a study involving Colombian hypertensive patients, the combination of olmesartan/amlodipine (20/5 mg, 40/5 mg, and 40/10 mg) was well-tolerated with minimal adverse effects such as headache, dizziness, and peripheral edema3. No treatment discontinuations were reported, underscoring the combination's safety over a 12-week period3.
Pharmacokinetics and Bioequivalence
The pharmacokinetics of olmesartan and amlodipine, whether administered separately or as a fixed-dose combination, have been shown to be bioequivalent. This means that the fixed-dose combination tablet provides similar exposure to the drugs as when they are taken separately, ensuring consistent efficacy and safety7. However, food intake can significantly reduce olmesartan exposure, which is an important consideration for clinical practice5.
Gender and Age-Based Efficacy
Research indicates that olmesartan/amlodipine is effective across different age groups and genders. Females tend to show slightly larger reductions in blood pressure compared to males, and the combination is effective in both younger and older patients4. This broad efficacy makes olmesartan a versatile option for diverse patient populations.
Conclusion
Olmesartan, particularly in combination with amlodipine, is an effective and safe option for managing hypertension. Even at lower doses like 5 mg, it provides significant blood pressure reductions and is well-tolerated across various patient demographics. These findings support the use of olmesartan as a reliable component of antihypertensive therapy.
Sources and full results
Most relevant research papers on this topic
Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone
The olmesartan/amlodipine combination effectively reduces blood pressure over 24 hours, including morning hours, with better 24-hour coverage and dose-related improvements in BP lowering homogeneity.
RCTA Double-Blind, Dose-Response Study of the Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescents with Hypertension
Olmesartan medoxomil is a safe and effective treatment for children with hypertension, resulting in significant blood pressure reductions.
RCT[PP.22.19] SAFETY AND EFFICIENCY OF OLMESARTAN AMLODIPINE IN COLOMBIAN HYPERTENSIVE PATIENTS (SOAT STUDY)
The combination of olmesartan and amlodipine in fixed doses provides excellent blood pressure control, with over 63% of patients achieving blood pressure goals and reducing pulse pressure by 13 mmHg.
Observational Study
Very Rigorous JournalEfficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients
Olmesartan/amlodipine is effective and safe in a wide range of patients with moderate-to-severe hypertension, regardless of age or hypertension severity, with potential differences in responsiveness between females and males.
RCT
Large Human TrialVery Rigorous JournalPharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and Amlodipine Besylate Fixed‐Dose Combination Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions
Olmesartan medoxomil/amlodipine besylate tablet (20 mg/5 mg) is bioequivalent and safe in healthy Chinese volunteers, with olmesartan exposure reduced after consuming a high-fat meal.
Very Rigorous JournalOlmesartan Medoxomil/Amlodipine
Olmesartan medoxomil/amlodipine effectively reduces blood pressure and is well-tolerated by patients with mild to severe hypertension.
RCTPharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed‐Dose Combination
The fixed-dose combination of amlodipine and olmesartan is bioequivalent to amlodipine 10 mg plus olmesartan medoxomil 40 mg, with dose-proportional total exposure.
RCTClinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Olmesartan medoxomil effectively reduces blood pressure in patients with essential hypertension, mild-to-moderate hypertension, and has potential benefits for atherosclerosis, cardiac remodeling, and type 2 diabetes.
Non-RCTAntihypertensive Efficacy of Olmesartan Medoxomil, a New Angiotensin II Receptor Antagonist, as Assessed by Ambulatory Blood Pressure Measurements
Olmesartan medoxomil is a safe and effective once-a-day treatment for hypertension, with similar safety profile to placebo.
RCTLarge Human Trial